抗CD20单克隆抗体治疗神经免疫相关疾病期间感染管理上海专家建议(2022)  

Expert Consensus on Infection Management for Anti-CD20 Monoclonal Antibody for the Treatment of Neuroimmune Diseases (2022)

作　　者：国家神经疾病医学中心 国家传染病医学中心 上海市医学会神经内科专科分会 上海免疫学会神经免疫专业委员会 上海市医学会感染病专科分会 陈向军[2] 邵凌云[2] National Center for Neurological Disorders;National Medical Center for Infectious Diseases;Shanghai Medical Association Branch of Neurology;Shanghai Immunology Society Branch of Neuroimmunology;Shanghai Medical Association Branch of Infectious Diseases;CHEN Xiang-jun;SHAO Lin-yun

机构地区：[1]不详 [2]复旦大学附属华山医院

出　　处：《中国临床神经科学》2022年第1期1-7,共7页Chinese Journal of Clinical Neurosciences

基　　金：上海申康医院发展中心临床3年行动计划(编号:SHDC2020CR2027B);国家和省级重大疾病多学科合作诊疗能力建设项目:2020年中央转移支付医疗卫生机构能力建设项目。

摘　　要：近年来抗CD20单克隆抗体作为一种快速起效的靶向B细胞药物,广泛应用于神经免疫相关疾病的治疗。然而长期临床应用免疫调节药物引起的相关感染风险不容小觑,亟需制定相应防范策略。经上海市多家医院神经内科、感染科和影像科专家共同讨论,对抗CD20单克隆抗体的最新临床研究进行分析,并总结在中国患者人群中的临床应用经验,形成抗CD20单克隆抗体感染风险管理策略的上海专家指导建议,包括感染风险的筛查、识别、预防和监测;为指导临床安全、有效应用抗CD20单克隆抗体治疗提供理论依据。In recent years, anti-CD20 monoclonal antibodies(mAbs), as a rapid-onset B-cell targeted drug, are widely used in the treatment of neuroimmune diseases. The long-term clinical application of immunomodulatory drugs requires attention to the risk of infection and mitigation strategies. With a panel of experts from departments of neurology, infectious diseases, and imaging in Shanghai, we reviewed the latest data of anti-CD20 mAbs combined with clinical practice experiences in China and develop this expert guidance. The infection risk management guidance is aiming to establish a practical risk management strategy framework, including early screening, identification, prevention and monitoring in order to achieve effective and safe application of anti-CD20 mAbs in the treatment of neuroimmune diseases.

关 键 词：抗CD20单克隆抗体 神经免疫相关疾病 感染风险管理 

分 类 号：R512.3[医药卫生—内科学] R742[医药卫生—临床医学]